Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) demonstrated substantial shareholder engagement at its annual general and special meeting held September 26, 2025, in Toronto. The meeting attracted holders representing 12 Class A multiple voting shares—each carrying 276,660 votes per share—and 1,769,228 Class B subordinate voting shares present either in person or by proxy. This participation accounted for 100% of Class A votes and 46.352% of Class B votes, reflecting significant investor interest in the company's strategic direction.
The high level of shareholder involvement is particularly noteworthy given Quantum BioPharma's focus on developing innovative treatments for challenging neurodegenerative and metabolic disorders, including alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing its lead compound, Lucid-MS, a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation represents the underlying mechanism of multiple sclerosis, positioning Lucid-MS as a potentially transformative therapy for this debilitating condition.
Beyond its pharmaceutical development pipeline, Quantum BioPharma maintains strategic business interests through its ownership stake in Unbuzzd Wellness Inc. The company retains 20.11% ownership of Unbuzzd Wellness as of March 31, 2025, along with royalty arrangements that include 7% of sales from the unbuzzd(TM) product until payments to Quantum BioPharma total $250 million, after which the royalty decreases to 3% in perpetuity. This diversified revenue stream provides financial stability while the company advances its core pharmaceutical research. Additional corporate information is available in the company's newsroom.
The shareholder meeting results underscore investor confidence in Quantum BioPharma's dual-track approach of developing novel pharmaceutical treatments while maintaining strategic investments and revenue-generating partnerships. The company's retention of 100% rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses ensures it maintains control over its core therapeutic development while leveraging consumer health products for near-term revenue generation.
